Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no im...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Drug Resistance 2020-01, Vol.3 (3), p.666-671
Hauptverfasser: Batista, Thales Paulo, Dal Molin, Graziela Zibetti
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 671
container_issue 3
container_start_page 666
container_title Cancer Drug Resistance
container_volume 3
creator Batista, Thales Paulo
Dal Molin, Graziela Zibetti
description Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.
doi_str_mv 10.20517/cdr.2020.27
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8992489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666547801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-aa548b3c445dd5ac6477e1a38ce235ff47ece7304d5fecdebd7ac4fe7951c7993</originalsourceid><addsrcrecordid>eNpVkc1LJDEQxcOCqKi3PS85erC1Ox-d7osig-4IgoO4sLdQnVSPWXqSMUkP-N_bs46ip3rFe7wq-BHysyrPWSkrdWFsnBSbVvWDHDKpmkJy9veAnKT0ryxL1jLGWrlPDriUDROiPiTrGXg6v1vczGiHdExoKSzB-ZTpeoDs_LgqIiaXMniDFLylfYjUeTsa55c0oU8uu43LrzQHurh-XEzms-tcDjFNkoYNRDcdMduCeHVM9noYEp7s5hH5c3vzNJsX9w-_72bX94XhjcgFgBRNx40Q0loJphZKYQW8Mci47Huh0KDipbCyR2OxswqM6FG1sjKqbfkRuXzvXY_dCq1BnyMMeh3dCuKrDuD0d8e7Z70MG920LRPNtuB0VxDDy4gp65VLBocBPIYxaVbXtRSqKaspevYeNTGkFLH_PFOV-j8bPbHRWzaaqSn-6-trn-EPKvwNvw-PSw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2666547801</pqid></control><display><type>article</type><title>Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Batista, Thales Paulo ; Dal Molin, Graziela Zibetti</creator><creatorcontrib>Batista, Thales Paulo ; Dal Molin, Graziela Zibetti</creatorcontrib><description>Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.</description><identifier>EISSN: 2578-532X</identifier><identifier>DOI: 10.20517/cdr.2020.27</identifier><identifier>PMID: 35582446</identifier><language>eng</language><publisher>United States: OAE Publishing Inc</publisher><ispartof>Cancer Drug Resistance, 2020-01, Vol.3 (3), p.666-671</ispartof><rights>The Author(s) 2020.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-aa548b3c445dd5ac6477e1a38ce235ff47ece7304d5fecdebd7ac4fe7951c7993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992489/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992489/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35582446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Batista, Thales Paulo</creatorcontrib><creatorcontrib>Dal Molin, Graziela Zibetti</creatorcontrib><title>Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?</title><title>Cancer Drug Resistance</title><addtitle>Cancer Drug Resist</addtitle><description>Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.</description><issn>2578-532X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkc1LJDEQxcOCqKi3PS85erC1Ox-d7osig-4IgoO4sLdQnVSPWXqSMUkP-N_bs46ip3rFe7wq-BHysyrPWSkrdWFsnBSbVvWDHDKpmkJy9veAnKT0ryxL1jLGWrlPDriUDROiPiTrGXg6v1vczGiHdExoKSzB-ZTpeoDs_LgqIiaXMniDFLylfYjUeTsa55c0oU8uu43LrzQHurh-XEzms-tcDjFNkoYNRDcdMduCeHVM9noYEp7s5hH5c3vzNJsX9w-_72bX94XhjcgFgBRNx40Q0loJphZKYQW8Mci47Huh0KDipbCyR2OxswqM6FG1sjKqbfkRuXzvXY_dCq1BnyMMeh3dCuKrDuD0d8e7Z70MG920LRPNtuB0VxDDy4gp65VLBocBPIYxaVbXtRSqKaspevYeNTGkFLH_PFOV-j8bPbHRWzaaqSn-6-trn-EPKvwNvw-PSw</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Batista, Thales Paulo</creator><creator>Dal Molin, Graziela Zibetti</creator><general>OAE Publishing Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?</title><author>Batista, Thales Paulo ; Dal Molin, Graziela Zibetti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-aa548b3c445dd5ac6477e1a38ce235ff47ece7304d5fecdebd7ac4fe7951c7993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Batista, Thales Paulo</creatorcontrib><creatorcontrib>Dal Molin, Graziela Zibetti</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Drug Resistance</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Batista, Thales Paulo</au><au>Dal Molin, Graziela Zibetti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?</atitle><jtitle>Cancer Drug Resistance</jtitle><addtitle>Cancer Drug Resist</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>3</volume><issue>3</issue><spage>666</spage><epage>671</epage><pages>666-671</pages><eissn>2578-532X</eissn><abstract>Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.</abstract><cop>United States</cop><pub>OAE Publishing Inc</pub><pmid>35582446</pmid><doi>10.20517/cdr.2020.27</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2578-532X
ispartof Cancer Drug Resistance, 2020-01, Vol.3 (3), p.666-671
issn 2578-532X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8992489
source PubMed Central Open Access; PubMed Central
title Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T12%3A43%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20HIPEC%20be%20used%20against%20platinum-resistance%20and%20for%20inducing%20sensitivity%20to%20PARP%20inhibitors%20in%20ovarian%20cancer?&rft.jtitle=Cancer%20Drug%20Resistance&rft.au=Batista,%20Thales%20Paulo&rft.date=2020-01-01&rft.volume=3&rft.issue=3&rft.spage=666&rft.epage=671&rft.pages=666-671&rft.eissn=2578-532X&rft_id=info:doi/10.20517/cdr.2020.27&rft_dat=%3Cproquest_pubme%3E2666547801%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2666547801&rft_id=info:pmid/35582446&rfr_iscdi=true